Background: ERCP requires patient cooperation and often prolonged sedation. In different areas of anesthetic practice, patient-controlled sedation with a target-controlled infusion (TCI) of propofol provides effective sedation. The aim of this study was to assess the safety and efficacy of the same system in patients undergoing ERCP. Methods: Twenty patients used the TCI system. Patients received oxygen at 2 L/min via nasal cannulae. By using pharmacokinetic TCI software modeling, an initial propofol target blood concentration (Ct) of 1.0 µg/mL was supplemented on patient demand with a handset that, when pressed twice within 1 second, increased the Ct of propofol by 0.2 µg/mL. The maximum permissible target concentration was set at 3.0 µg/mL to prevent oversedation. Results: Sixteen patients used the system successfully throughout the procedure. The Ct propofol ranged from 1.2 to 2.6 µg/mL, and the number of successful handset activations (after commencement of the ERCP) ranged from 0 to 3. In 3 patients, the ceiling Ct propofol was attained without adequate sedation and the system was manually overridden. The system failed in 1 case because of patient confusion. There were no episodes of hemodynamic instability, airway obstruction, or significant oxygen desaturation. Endoscopist and patient satisfaction were high. Four patients were oversedated according to our criteria at the end of the procedure, but all were awake within 5 minutes of arrival in the recovery area. Conclusions: Patient-maintained sedation with TCI propofol was safe and fully effective in 16 patients. Ease of endoscopy was rated high by the endoscopists, and all patients were well satisfied with their sedation. Adjustments to the software programming are being evaluated to increase the safety profile to avoid oversedation. (Gastrointest Endosc 2001;54:14-7.)
Sedation for upper endoscopy is commonly provided by the endoscopist with intermittent boluses of a benzodiazepine, such as midazolam. The safety of this technique has been questioned with a reported morbidity of 1/200 and mortality of 1/2000, predominately from cardiorespiratory complications. 1 Over 50% of the reported morbidity and mortality is due to hypoxemia. 2 Routine use of supplemental oxygen and minimum standards for monitoring are now recommended. 3 Low-dose propofol has anxiolytic and amnesic properties and when it is used as a sedative, patients have expressed a high degree of satisfaction. 4 Its pharmacokinetic profile results in a rapid recovery, and a variety of intermittent bolus and infusion regimens for sedation have been evaluated in the endoscopy suite. [5] [6] [7] [8] [9] [10] [11] Target-controlled infusion (TCI) of propofol is used in anesthetic practice and uses a pharmacokinetic model to achieve and maintain a selected target blood propofol concentration, 12 thereby overcoming the varying effect that results from peak and trough concentrations after bolus administration. The TCI system has been further developed to incorporate a handset so that patients can titrate the sedative effect to their own needs, thus combining the benefits of TCI with the safety of a patient-controlled feedback loop. Patient-controlled sedation with propofol TCI has been shown to be safe and effective in reducing preoperative anxiety levels when used as premedication before ambulatory surgical procedures, with no patient becoming oversedated. 13 The system has also been used for patients having surgery under local or regional blockade with no cardiovascular instability, little oversedation, and high patient satisfaction. 14 During the course of an ERCP, the level of stimulation and discomfort varies. Individuals also vary in their sensitivity to sedative drugs and have different preferences in terms of the level of sedation. ERCP procedures are often prolonged and can be technically demanding, requiring a high degree of patient cooperation. Therefore the safety and efficacy of this combined patient-and target-controlled system was
PATIENTS AND METHODS
The study protocol was approved by the ethics committee of our hospital. Informed written consent was obtained from 20 patients (median age 56 years, range 29-79 years, 10 men) who were enrolled and studied prospectively. According to the American Society of Anesthesiology (ASA) physical status classification, 12 patients were in ASA class I, 4 in ASA class II, and 4 in ASA class III. Any patient considered fit for sedation and scheduled for an elective diagnostic or therapeutic ERCP was considered for inclusion in the trial. Exclusion criteria included inability to use the handset, history of opioid use, and previous requirement for general anesthesia for the procedure.
Intravenous access was established in the right hand; baseline observations were made of oxygen saturation (SaO 2 ), heart rate, and blood pressure; and oxygen supplementation was begun at 2 L/min via nasal cannulae. Propofol TCI was delivered by a Graseby 3400 infusion pump (Graseby Medical, Watford, U.K.), the rate of which was controlled by a microprocessor system, programmed with the pharmacokinetic data describing the distribution and elimination of propofol (Anesthesia Technology Ltd., Wetherby, UK). 12, 13 The system displays the calculated effect-site concentration (i.e., theoretical brain concentration), in addition to the target blood concentration of propofol, based on the patient's age and weight, which were entered into the microprocessor. Connection of a handset to the microprocessor enables the patient to increase the target blood concentration of propofol.
The propofol infusion (1% with lidocaine 20 mg per 50 mL to eliminate pain on injection) was started at an initial target blood concentration of 1.0 µg/mL in the endoscopy recovery area where full resuscitation facilities were available. After approximately 8 minutes, when the effectsite concentration of propofol was estimated to be 0.9 µg/mL, the patient was given the handset and directed to "double press" the button as often as necessary to make themselves sleepy. Successful activation of the handset by double pressing the button within 1 second increased the target blood concentration of propofol by 0.2 µg/mL. There was a lockout period of 2 minutes during which no further target increases were possible. The maximum permissible target blood concentration of propofol was set at 3.0 µg/mL. If no successful demands were detected within a 6-minute period, the microprocessor would reduce the target blood concentration automatically by 0.2 µg/mL. Patients were allowed a maximum of 20 minutes to titrate themselves to a level of sedation that they were happy with before the start of the procedure. Lidocaine throat spray (10%) was given before insertion of the endoscope. During endoscopy, the only encouragement the patient was given was to "press the button" if they wanted to be more sleepy. Heart rate, noninvasive blood pressure, and SaO 2 (Critikon Dinamap Plus Vital Signs Monitor, Tampa, Fla.) were recorded every 5 minutes. The sedation score for each patient (Table 1) was determined by the anesthetist who was present at all times. This was recorded immediately before endoscopy, at the end of endoscopy, and on arrival in the recovery area.
After endoscopy, the endoscopist completed a 6-point questionnaire on the ease of the procedure ( Table 2 ). The need for the anesthetist to intervene to support the airway or take over the sedation from the patient was considered a failure of the technique. Two hours after endoscopy, the patients completed a questionnaire designed to determine what they remembered of the procedure and to assess satisfaction.
RESULTS
Twelve patients had either a straightforward ERCP or ERCP with sphincterotomy (mean duration 16.1 minutes, range 7-27 minutes). Eight patients had more complex therapeutic procedures including stent change and lithotripsy, all involving repeated instrumentation of the bile duct. Mean duration of these procedures was 36.5 minutes (range 15-55 minutes). There were no episodes of hemodynamic instability, and arterial oxygen saturation did not decrease below 93% in any patient.
Of the twenty patients, 16 managed to use the system satisfactorily to maintain a level of sedation that was adequate for their comfort and the completion of the procedure. The recorded target blood concentrations of propofol did not vary much during the course of the procedure (Table 3 ). In keeping with this finding, the number of successful handset activations during the procedure ranged from 0 to 3, with a mean of 1.6 (Table 4) .
Sedation scores are shown in Table 5 . Four patients became oversedated by our criteria (sedation score ≥5). Two were arousable only to shaking at the end of the procedure, and two were unrousable, one just before insertion of the endoscope and the other at the end of the procedure. However, the latter patient had reached a sedation score 3 (eyes open, slurred speech) within 5 minutes of arrival in the recovery room. In each case the procedure was completed successfully and the patient recovered without intervention.
There were 4 system failures. In 3 patients the system failed because the programmed ceiling target blood concentration of propofol was too low. The system failed during 1 procedure because of patient confusion. In these 4 patients, control of sedation was taken over by the anesthetist and the ERCP successfully concluded.
When the endoscopist rated the ease of the procedure, 14 of the 16 procedures in which the system was successful had a rating of 8 or less (6 being the best possible score, 24 the worst). In 2 the endoscopist scores were greater than 9, indicating a moderate degree of noncooperation by the patient.
All of the patients were happy with the sedation they received for the endoscopy, and all said they would use the system again. Of the 16 patients in whom the system was used successfully, 7 recalled arriving in the endoscopy room and receiving the throat spray. Two remembered the insertion of the endoscope, but neither of them recalled it as an unpleasant experience.
DISCUSSION
Initial evaluation of this patient-controlled sedation system for ERCP in 20 patients has provided useful practical data. The system was used successfully by 80% of the patients. The median target blood concentration of propofol required for adequate sedation was higher than that achieved in previous studies of premedication and sedation during surgery under local anesthesia. 13, 14 However, a target of 4.5 µg/mL was required in a previous study of propofol TCI during endoscopic procedures. 9 In 3 patients in the present study the preprogrammed maximum permissible target concentration of 3.0 µg/mL produced inadequate sedation, resulting in failure of the system for these patients. This demonstrates the need for a higher level of sedation during uncomfortable endoscopic procedures compared with the low level needed during surgery under good regional or local blockade. 14 The low number of handset activations during procedures that have a relatively long duration indicates that patients were adequately sedated at the start and demonstrates the steady state conditions that result from the TCI system. There is variation among individuals in the actual Ct propofol that is required for adequate sedation. Once patients have titrated the dosage to their level of comfort, they need to use the handset only a few times to maintain this level during the course of the procedure.
Until recently, endoscopists frequently induced sedation by administration of high-dose boluses of a benzodiazepine, often combined with an opioid. 1 Fortunately, low-dose sedation is becoming incorporated into routine practice, but this may be associated with little in the way of amnesia. Indeed, with 15 Willingness to repeat the examination may be reduced in these patients. Patients undergoing therapeutic ERCP often require a series of such procedures, and some may be so traumatized by their first experience that they refuse further procedures unless formally anesthetized. In the patients who used the TCI system successfully, the level of amnesia was high, with only 2 patients remembering intubation and neither finding it an unpleasant experience. Further, all patients were willing to use the technique again if another procedure was required in the future. The system was safe insofar as there were no episodes of desaturation below an arterial blood oxygen level of 93% (while receiving oxygen at 2 L/min via nasal cannulae) and no instances of hemodynamic compromise. However, 4 patients were considered to be oversedated at the end of the procedure, and this is a concern. Patients undergoing this procedure should receive sedation to a level at which they remain able to communicate and to respond to speech. Deeper levels of sedation should be provided by an anesthetist. Our intention, therefore, is to add a manual decrement in the target blood propofol concentration of 0.2 µg/mL if the patient fails to open his/her eyes to command at any point during the procedure (assessed by the nurse responsible for the patient's airway). Patients who can obey this simple command are unlikely to lose control of their airway, and therefore should be safe in the care of the endoscopist and nursing staff in the endoscopy suite.
The adequacy of conventional sedation for patients undergoing ERCP is a question that is poorly addressed by published data. It is generally accepted that patients undergoing ERCP sustain more complications than those undergoing simple diagnostic upper endoscopy because of the longer duration of the procedure and the higher doses of sedative and analgesic medication required to complete the procedure. However, only limited data are available on patient and endoscopist satisfaction with sedation levels and the safety of the procedure. Initial experience with the TCI system used in this study confirms that endoscopist and patient satisfaction were high. Further refinement of the system with respect to the maximum permissible target blood concentration of propofol and handset activation is being evaluated, and a randomized, prospective comparison trial with standard bolus benzodiazepine sedation is planned. However, at the present time for safety reasons, the administration of propofol in the endoscopy suite should continue to be supervised by an anesthetist or properly trained nonanesthetist physician.
